Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Promising antitumour activity and acceptable safety profile in patients with HER2-mutated advanced non-small cell lung cancer who had received at least one prior platinum-based chemotherapy
Results from the BIG 1-98 study
Results from the KAMILLA exploratory analysis
Approval is based on findings from the KEYNOTE‑177 study
Efficacy was investigated in the JAVELIN Bladder 100 trial
It was intended for the treatment of tenosynovial giant cell tumour
Efficacy was investigated in FeDeriCa trial
Findings from a retrospective study presented at ESMO World GI 2020 Virtual
Results from an additional analyses of phase III POLO trial by age group presented at ESMO World GI 2020 Virtual
Results of the CheckMate 459 study long-term survival outcomes presented at ESMO World GI 2020 Virtual
A comprehensive new edition presents the latest information in early-, intermediate- and advanced-stage hepatocellular carcinoma
It is intended for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian cancer, and carcinoma of the cervix
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
